PFE241206P22500
- 0.01
- 0.000.00%
Pfizer Newsroom
Riot Shares Jump 13% as Activist Starboard Takes Stake in Bitcoin-Miner
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Are Pfizer Inc.'s (NYSE:PFE) Mixed Financials Driving The Negative Sentiment?
Pfizer Announces Results From PATINA Trial
Express News | Pfizer Inc - Overall Survival Data Not yet Mature
Pfizer's IBRANCE in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients With HR+, HER2+ Metastatic Breast Cancer
Express News | Pfizer’s Ibrance® in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 Patina Study in Patients With Hr+, Her2+ Metastatic Breast Cancer
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $28 to $33
Today's Analyst Rating | Citi Cuts Its Price Target Cut on Johnson & Johnson to $175, Deutsche Bank Upgrades Coca-Cola to Buy
Pfizer (PFE) Gets a Hold From J.P. Morgan
Cautious Outlook: Pfizer's EPS Downgrade and Conservative Guidance Prompt Hold Rating
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer Options Spot-On: On December 11th, 215.48K Contracts Were Traded, With 3.54 Million Open Interest
Nasdaq Surges Past 20,000 for the First Time, Powered by Tech Giants | Wall Street Today
Pfizer's Options: A Look at What the Big Money Is Thinking
Amazon, Pfizer Execs Seek Common Ground With RFK Jr on Climate Risks to Health
10 Health Care Stocks Whale Activity In Today's Session
Pfizer Is Maintained at Buy by Guggenheim